Current concepts and review of alefacept in the treatment of psoriasis.
Krueger
Gerald G
GG
Department of Dermatology, 4B454 School Medicine, University of Utah Health Sciences Center, 30 N 1900 E, Salt Lake City, UT 84132-2409, USA. gerald.krueger@derm.med.utah.edu
D000077944:Alefacept; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D008297:Male; D020714:Maximum Tolerated Dose; D011379:Prognosis; D011565:Psoriasis / Q000175:diagnosis / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage* / Q000493:pharmacokinetics; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
D011993:Recombinant Fusion Proteins; D000077944:Alefacept